SAFC is pleased to announce that two leading Asian biopharmaceutical companies have signed commercial sales and licensing contracts for the purchase of their off-the-shelf cell line production platform CHOZN®. The customers have confirmed that they will use the platform as a key component in support from development stage through commercialization.
This acts a step towards gaining greater traction in the Asia Pacific market, which SAFC sees as an important market to align with. The purchases also support SAFC’s drive to further integrate the CHOZN platform in the biopharmaceutical space and help customers to drive innovation.
Please see the full press release below.
SAFC Strengthens Biopharmaceutical Market Presence in Asia with Commercial Licensing of CHOZN® Cell Line Bioproduction Platform
ST LOUIS, MO – June 4, 2013 – Sigma-Aldrich Corporation (NASDAQ: SIAL) today announced that SAFC® Commercial (www.safcglobal.com), its custom manufacturing services business unit, has won commercial sales and licensing contracts with two leading Asian biopharmaceutical companies for the purchase of CHOZN®, their off-the-shelf cell line production platform. The contracts feature the CHOZN® Platform system as a key component of each customer’s global biotherapeutic commercialization strategy.
The CHOZN® Platform consists of the CHOZN® GS-/- CHO cell line and an optimized set of cGMP-produced, chemically defined (CD) media and feeds designed specifically for the cell line to maximize the production of monoclonal antibodies and other r-proteins. Powered by Sigma-Aldrich’s CompoZr® Zinc Finger Nuclease (ZFN) technology, SAFC’s cGMP-produced and tested CHOZN® cell line was the first commercially available glutamine synthetase (GS) knockout CHO line on the market.
The CHOZN® GS (-/-) platform provides a best-in-class stable cell line that results in faster, simpler selection and scale-up of high-producing manufacturing clones, saving weeks of development. In combination with the ZFN technology, CHOZN® provides a gateway from development through commercialization.
In addition to the cell line, media and feed, SAFC provides extensive user support. This includes working with the customer on protocols from transfection through to scale-up in bioreactors, as well as providing comprehensive cell line safety testing and development history packages. In addition, the lean CD media and feed system allows for tunable product quality.
“We are seeing a great deal of interest in our CHOZN® Platform in Asia as numerous pharmaceutical companies in the region are looking to enter this market,” said Dr. Kevin Kayser, Director of the CHOZN® Platform for SAFC. “Going forward, we expect to see increased engagement throughout the region based on our ability to accelerate upstream development timelines to positively impact the potential profitability of biotherapeutic products.”
For more information on CHOZN products and services please click here.
For any questions or inquiries please contact us here.